Cargando…

Clinical implications of DLL4 expression in gastric cancer

BACKGROUND: Delta-like ligand 4 (DLL4)-Notch signaling plays a key role in tumor neovascular development and angiogenesis during tumor growth. The clinical significance of DLL4 expression in gastric cancer has not been clarified. METHODS: Gastric cancer cell lines and 180 gastric cancer patients wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishigami, Sumiya, Arigami, Takaaki, Uenosono, Yoshikazu, Okumura, Hiroshi, Kurahara, Hiroshi, Uchikado, Yasuto, Setoyama, Tetsuro, Kita, Yoshiaki, Kijima, Yuko, Nishizono, Yuka, Nakajo, Akihiro, Owaki, Tetsuro, Ueno, Shinichi, Natsugoe, Shoji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751047/
https://www.ncbi.nlm.nih.gov/pubmed/23898884
http://dx.doi.org/10.1186/1756-9966-32-46
_version_ 1782281521550327808
author Ishigami, Sumiya
Arigami, Takaaki
Uenosono, Yoshikazu
Okumura, Hiroshi
Kurahara, Hiroshi
Uchikado, Yasuto
Setoyama, Tetsuro
Kita, Yoshiaki
Kijima, Yuko
Nishizono, Yuka
Nakajo, Akihiro
Owaki, Tetsuro
Ueno, Shinichi
Natsugoe, Shoji
author_facet Ishigami, Sumiya
Arigami, Takaaki
Uenosono, Yoshikazu
Okumura, Hiroshi
Kurahara, Hiroshi
Uchikado, Yasuto
Setoyama, Tetsuro
Kita, Yoshiaki
Kijima, Yuko
Nishizono, Yuka
Nakajo, Akihiro
Owaki, Tetsuro
Ueno, Shinichi
Natsugoe, Shoji
author_sort Ishigami, Sumiya
collection PubMed
description BACKGROUND: Delta-like ligand 4 (DLL4)-Notch signaling plays a key role in tumor neovascular development and angiogenesis during tumor growth. The clinical significance of DLL4 expression in gastric cancer has not been clarified. METHODS: Gastric cancer cell lines and 180 gastric cancer patients were enrolled. DLL4 expression in gastric cancer cells and stroma was identified and evaluated immunohistochemically. The association between DLL4 and clinicopathological factors was also assessed. RESULTS: DLL4 expression was identified in the cellular membrane and cytoplasm of gastric cancer cells by immunoblotting and immunohistochemical staining. DLL4 positivity in cancer cells and stroma was found in 88 (48%) and 41 (22%) of the 180 gastric cancer patients respectively. Both cancer and stromal DLL4 expression significantly correlated with more advanced tumor depth, nodal involvement, and lymphatic and venous invasion. A strongly positive association between cancerous and stromal DLL4 expression was identified (p < 0.01). Both cancerous and stromal DLL4 expression were prognostic markers in gastric cancer as determined by univariate analysis. CONCLUSIONS: Cancerous and stromal DLL4 expression was found in 48% and 22% in gastric cancer, and significantly affected postoperative clinical outcomes. Cancerous and stromal DLL4 expression may be an effective target of anti-DLL4 treatment in gastric cancer.
format Online
Article
Text
id pubmed-3751047
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-37510472013-08-24 Clinical implications of DLL4 expression in gastric cancer Ishigami, Sumiya Arigami, Takaaki Uenosono, Yoshikazu Okumura, Hiroshi Kurahara, Hiroshi Uchikado, Yasuto Setoyama, Tetsuro Kita, Yoshiaki Kijima, Yuko Nishizono, Yuka Nakajo, Akihiro Owaki, Tetsuro Ueno, Shinichi Natsugoe, Shoji J Exp Clin Cancer Res Research BACKGROUND: Delta-like ligand 4 (DLL4)-Notch signaling plays a key role in tumor neovascular development and angiogenesis during tumor growth. The clinical significance of DLL4 expression in gastric cancer has not been clarified. METHODS: Gastric cancer cell lines and 180 gastric cancer patients were enrolled. DLL4 expression in gastric cancer cells and stroma was identified and evaluated immunohistochemically. The association between DLL4 and clinicopathological factors was also assessed. RESULTS: DLL4 expression was identified in the cellular membrane and cytoplasm of gastric cancer cells by immunoblotting and immunohistochemical staining. DLL4 positivity in cancer cells and stroma was found in 88 (48%) and 41 (22%) of the 180 gastric cancer patients respectively. Both cancer and stromal DLL4 expression significantly correlated with more advanced tumor depth, nodal involvement, and lymphatic and venous invasion. A strongly positive association between cancerous and stromal DLL4 expression was identified (p < 0.01). Both cancerous and stromal DLL4 expression were prognostic markers in gastric cancer as determined by univariate analysis. CONCLUSIONS: Cancerous and stromal DLL4 expression was found in 48% and 22% in gastric cancer, and significantly affected postoperative clinical outcomes. Cancerous and stromal DLL4 expression may be an effective target of anti-DLL4 treatment in gastric cancer. BioMed Central 2013-07-30 /pmc/articles/PMC3751047/ /pubmed/23898884 http://dx.doi.org/10.1186/1756-9966-32-46 Text en Copyright © 2013 Ishigami et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Ishigami, Sumiya
Arigami, Takaaki
Uenosono, Yoshikazu
Okumura, Hiroshi
Kurahara, Hiroshi
Uchikado, Yasuto
Setoyama, Tetsuro
Kita, Yoshiaki
Kijima, Yuko
Nishizono, Yuka
Nakajo, Akihiro
Owaki, Tetsuro
Ueno, Shinichi
Natsugoe, Shoji
Clinical implications of DLL4 expression in gastric cancer
title Clinical implications of DLL4 expression in gastric cancer
title_full Clinical implications of DLL4 expression in gastric cancer
title_fullStr Clinical implications of DLL4 expression in gastric cancer
title_full_unstemmed Clinical implications of DLL4 expression in gastric cancer
title_short Clinical implications of DLL4 expression in gastric cancer
title_sort clinical implications of dll4 expression in gastric cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3751047/
https://www.ncbi.nlm.nih.gov/pubmed/23898884
http://dx.doi.org/10.1186/1756-9966-32-46
work_keys_str_mv AT ishigamisumiya clinicalimplicationsofdll4expressioningastriccancer
AT arigamitakaaki clinicalimplicationsofdll4expressioningastriccancer
AT uenosonoyoshikazu clinicalimplicationsofdll4expressioningastriccancer
AT okumurahiroshi clinicalimplicationsofdll4expressioningastriccancer
AT kuraharahiroshi clinicalimplicationsofdll4expressioningastriccancer
AT uchikadoyasuto clinicalimplicationsofdll4expressioningastriccancer
AT setoyamatetsuro clinicalimplicationsofdll4expressioningastriccancer
AT kitayoshiaki clinicalimplicationsofdll4expressioningastriccancer
AT kijimayuko clinicalimplicationsofdll4expressioningastriccancer
AT nishizonoyuka clinicalimplicationsofdll4expressioningastriccancer
AT nakajoakihiro clinicalimplicationsofdll4expressioningastriccancer
AT owakitetsuro clinicalimplicationsofdll4expressioningastriccancer
AT uenoshinichi clinicalimplicationsofdll4expressioningastriccancer
AT natsugoeshoji clinicalimplicationsofdll4expressioningastriccancer